Litcius/Paper detail

Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study

Jing Pan, Kaiting Tang, Yuechen Luo, Samuel Seery, Yue Tan, Biping Deng, Feng Liu, Xiuwen Xu, Zhuojun Ling, Weiliang Song, Jinlong Xu, Jiajia Duan, Zelin Wang, Chunyu Li, Kai Wang, Yi-Bing Zhang, Xinjian Yu, Qinlong Zheng, Liping Zhao, Jiecheng Zhang, Alex H. Chang, Xiaoming Feng

2023The Lancet Oncology65 citationsDOI

Topics & Concepts

MedicineMinimal residual diseaseAdverse effectInternal medicineRefractory (planetary science)CD22Clinical endpointAcute lymphocytic leukemiaGastroenterologyPhases of clinical researchChimeric antigen receptorCD20HematologyCytokine release syndromeOncologyImmunologyClinical trialLeukemiaLymphomaImmunotherapyCancerBiologyAstrobiologyLymphoblastic LeukemiaCAR-T cell therapy researchAcute Lymphoblastic Leukemia researchCutaneous lymphoproliferative disorders research
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study | Litcius